Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P22466

UPID:
GALA_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P22466; Q14413

BACKGROUND:
The Galanin peptides, identified by the unique identifier P22466, serve as endocrine hormones with critical roles across both central and peripheral nervous systems. Their interaction with GALR1, GALR2, and GALR3 receptors modulates numerous vital processes, including smooth muscle contraction, hormone release, and adrenal function.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Galanin peptides could open doors to potential therapeutic strategies, especially considering their involvement in Epilepsy, familial temporal lobe, 8. This disease's link to Galanin peptides underscores the importance of further research into their therapeutic applications.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.